Adenomas hipofisarios secretores de tirotropina: Tirotropinoma o TSH-oma. Artículo de Revisión
DOI:
https://doi.org/10.18041/1900-7841/rcslibre.2020v15n2.7761Palabras clave:
Hipertiroidismo central, Tirotropinoma (TSHoma), Adenoma secretor de TSHResumen
Los tirotropinomas son adenomas hipofisarios productores de tirotropina (hormona estimulante de tiroides), representan una causa poco común de hipertiroidismo menos del 1% de los casos totales y menos del 3% de todos los tumores hipofisiarios. Se consideran tumores infrecuentes y de difícil diagnóstico, pero con un incremento de su incidencia en los últimos años por una mayor sospecha de la misma. Esta entidad se caracteriza bioquímicamente por tener niveles de TSH normal o alta, asociada a concentraciones séricas altas de tiroxina total y libre (T4) y triyodotironina (T3), pero sin contar con una pruebas única de diagnóstico, asociada a manifestaciones clínicas diversas y variables entre cada paciente, por lo cual debería considerarse un reto diagnóstico en la práctica clínica, asociado a un retraso en el tratamiento oportuno, por esta razón nos planteamos como objetivo realizar una actualización sobre los adenomas hipofisarios productores de tirotropina tanto en su definición, epidemiologia, manifestaciones clínicas, diagnóstico y tratamiento, demostrando la evidencia que existe al respecto, para lograr aumentar la sospecha de esta patología, con un enfoque integral, un diagnóstico y tratamiento oportuno.
Descargas
Referencias
Gershengorn MC, Weintraub BD. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of ‘inappropriate secretion of TSH’ J Clin Invest. 1975;56:633–642. https://doi.org/10.1172/JCI108133
Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610. https://doi.org.10.1210/edrv-17-6-610
Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:597–606. https://doi.org.10.1016/j.beem.2009.05.006
Gurnell M, Visser TJ, Beck-Peccoz P, Chatterjee VKK. Resistance to thyroid hormone. In: Jameson LJ, DeGroot LJ, editors. Endocrinology, Adult and Pediatric. ed 6. II. Philadelphia: Saunders Elsevier; 2010;pp1745–1759. https://doi.org/10.1016/j.jss.2010.10.017
Hamilton C, Adams LC, Maloof F Hyperthyroidism due to thyrotropin-producing pituitary chromophobe adenoma. N Engl J Med 1970; 283:1077-1080. https://doi.org/10.1056/NEJM197011122832003
Onnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab. 2013;98:626–635. https://doi.org/10.1210/jc.2012-3362
Yamada S et al (2014) Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg 121(6):1462–1473. https://doi.org/10.3171 / 2014.7.JNS1471
Nakayama Y, Jinguji S, Kumakura S, Nagasaki K, Natsumeda M, Yoneoka Y, Saito T, Fujii Y. Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report. Pituitary. 2012 Mar;15(1):110-5. https://doi.org/10.1007/s11102-010-0275-y
Weiss, RE., Refetoff, S., Adenomas hipofisiarios secretores de TSH. [Monografía en Internet]. Ross, DS., (Ed): Uptodate; 2019 [acceso 29 de diciembre de 2020] Disponible en: http://www.uptodate.com/
Soubhi Nizam M, Kennedy L. Co-occurrence of thyroid binding globulin excess and a pituitary macroadenoma containing thyroid stimulating hormone-producing cells. Postgrad Med J. 2004; 80: 114-115. https://doi.org/10.1136/pmj.2003.009514
Roelfsema F, Kok S, Kok P, Pereira AM, Biermasz NR, Smit JW, Frolich M, Keenan DM, Veldhuis JD, Romijn JA. Pituitary-hormone secretion by thyrotropinomas. Pituitary. 2009; 12 : 200–210. https://doi.org/10.1007/s11102-008-0159-6
Okuma H, Hashimoto K, Ohashi T, Mihara M, Minami I, Izumiyama H, Sasaki S, Inoshita N, Nishioka H, Yamada S, Yoshimoto T. A case of TSH-secreting pituitary adenoma with cyclic fluctuations in serum TSH levels. Endocr J. 2018; 65 : 737–746. https://doi.org/10.1507/endocrj.EJ18-0006
Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76-82. https://doi.org/10.1159 / 000351007
Kamoun M., D’Herbomez M., Lemaire C., Fayard A., Desailloud R., Huglo D., Wemeau J.L., Coexistence of thyroidstimulating hormone-secreting pituitary adenoma and graves hyperthyroidism. Eur. Thyroid J. 3(1), 60–64 (2014). https://doi.org/10.1159/000355386
Socin HV, Chanson P, Delemer B et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003; 148:433–442. https://doi.org/10.1530/eje.0.1480433
Beck-Peccoz P, Persani L, Faglia G., Glycoprotein hormone α-subunit in pituitary adenomas. Trends Endocrinol Metab, 1992; 3:41–45. https://doi.org/10.1016/1043-2760(92)90041-x
Refetoff S, Dumitrescu AM. Resistance to thyroid hormone; in: Thyroid Disease Manager, chapter 16D. 2010. http://www.thyroidmanager.org
Jailer JW, Holub DA. Remission of Graves’ disease following radiotherapy of a pituitary neoplasm. Am J Med. 1960;28:497–499. https://doi.org/10.1016/0002-9343(60)90181-9
Tjörnstrand A, Nyström HF. Diagnostic approach to TSHproducing pituitary adenoma. Eur J Endocrinol. 2017. 177:R183–R197. https://doi.org/10.1530/EJE-16-1029
Beck-Peccoz P, Persani L, Lania A. Thyrotropin-Secreting Pituitary Adenomas. Endotext [Internet]. 2019 Jan 11 [cited 2021 Jul 15]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK278978/
Hung-Juan F, Yang-Fang L, Yu F, Li-Yong Z, Ya-Zhuo Z. Immunohistochemical expression on somatostatin receptor subtypes 2 and 5 in thyrotropin-secreting pituitary adenomas: a consecutive case series of pituitary adenomas. Int J Clin Exp Pathol 2017; 10(1): 479-488. https://doi.org/10.1016 / j.pathol.2017.10.024
Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf). 2005 Feb;62(2):176-81. https://doi.org/10.1111/j.1365-2265.2004.02192.x
Song M, Wang H, Song L et al. Ectopic TSH-secreting pituitary tumor: a case report and review of prior cases. BMC Cancer 14:544 34. 2015. https://doi.org/10.1186/1471-2407-14-544
Wang Q, Lu XJ, Sun J, Wang J, Huang CY, Wu ZF. Ectopic suprasellar TSH-secreting pituitary adenoma: case report and literature review. World Neurosurg 2016. 95(617):e13. https://doi.org/10.1016 / j.wneu.2016.08.062
Beck-Peccoz P, Persani L, Lania A. Thyrotropin-Secreting Pituitary Adenomas. Endotext [Internet]. 2019 Jan 11 [cited 2020 Dec 15]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK278978/
Kleinschmidt-DeMasters B. Histological features of pituitary adenomas and sellar region masses. Curr Opin Endocrinol Diabetes Obes 2016; 23: 476-484. https://doi.org/10.1097/MED.0000000000000293
Hannoush ZC, Weiss RE. Defects of Thyroid Hormone Synthesis and Action. Endocrinol Metab Clin North Am. 2017 Jun;46(2):375-388. https://doi.org/10.1016/j.ecl.2017.01.005
Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999 Feb;84(2):476-86. https://doi.org/10.1210/jcem.84.2.5505
Beck-Peccoz P, Persani L. TSH-induced hyperthyroidism caused by a pituitary tumor. Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):524-8; quiz following p528. https://doi.org/10.1038/ncpendmet0276
Webster J, Peters JR, John R, Smith J, Chan V, Hall R, Scanlon MF. Pituitary stone: two cases of densely calcified thyrotropin-secreting pituitary adenomas. Clin Endocrinol (Oxf) 1994; 40:137-43. https://doi.org/10.1111/j.1365-2265.1994.tb02456.x
Dyer MW, Gnagey A, Jones BT, Pula RD, Lanier WL, Atkinson JLD, Pasternak JJ. Perianesthetic Management of Patients With Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas. J Neurosurg Anesthesiol. 2017 Jul;29(3):341-346. https://doi.org/10.1097/ANA.0000000000000325
Malchiodi E, Profka E, Ferrante E, Sala E, Verrua E, Campi I, Lania AG, Arosio M, Locatelli M, Mortini P, Losa M, Motti E, Beck-Peccoz P, Spada A, Mantovani G. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab. 2014 Jun;99(6):2069-76. https://doi.org/10.1210/jc.2013-4376
Kao YH, Chang TJ, Huang TS. Thyrotropin-secreting pituitary tumor presenting with congestive heart failure and good response to dopaminergic agonist cabergoline. J Formos Med Assoc. 2013 Nov;112(11):721-4. https://doi.org/10.1016/j.jfma.2012.07.015
Mulinda JR, Hasinski S, Rose LI. Successful therapy for a mixed thyrotropin-and prolactin-secreting pituitary macroadenoma with cabergoline. Endocr Pract. 1999 Mar-Apr;5(2):76-9. https://doi.org/10.4158/EP.5.2.76
Mouton F, Faivre-Defrance F, Cortet-Rudelli C, Assaker R, Soto-Ares G, Defoort-Dhellemmes S, Blond S, Wemeau JL, Vantyghem MC. TSH-secreting adenoma improved with cabergoline. Ann Endocrinol (Paris). 2008 Jun;69(3):244-8. https://doi.org/10.1016/j.ando.2008.02.001
Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53. https://doi.org/10.1210/jcem.86.6.7593
Fliers E, van Furth WR, Bisschop PH. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin Endocrinol (Oxf). 2012 Nov;77(5):788-90. https://doi.org/10.1111/j.1365-2265.2012.04405.x
Neggers SJ, van der Lely AJ. Medical approach to pituitary tumors. Handb Clin Neurol. 2014;124:303-16. https://doi.org/10.1016/B978-0-444-59602-4.00020-4
Gatto F, Grasso LF, Nazzari E, Cuny T, Anania P, Di Somma C, Colao A, Zona G, Weryha G, Pivonello R, Ferone D. Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? Pituitary. 2015 Oct;18(5):583-91. https://doi.org/10.1007/s11102-014-0611-8
Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients. Thyroid. 2015 Aug;25(8):877-82. https://doi.org/10.1089/thy.2015.0041
Blackhurst G, Strachan MW, Collie D, et al. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clinical Endocrinology. 2002 Sep;57(3):401-404. https://doi.org/10.1046/j.1365-2265.2002.01549.x
Chaiamnuay S, Moster M, Katz MR, Kim YN. Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy. Pituitary. 2003 Sep;6(2):109-13. https://doi.org/10.1023/b:pitu.0000004802.47010.00
Araujo PB, Vieira Neto L, Gadelha MR. Pituitary tumor management in pregnancy. Endocrinol Metab Clin North Am. 2015 Mar;44(1):181-97. https://doi.org/10.1016/j.ecl.2014.10.015
Bolz M, Körber S, Schober HC. TSH-sezernierendes Hypophysenadenom (TSHom) - seltene Ursache einer Hyperthyreose in der Schwangerschaft [TSH secreting adenoma of pituitary gland (TSHom) - rare cause of hyperthyroidism in pregnancy]. Dtsch Med Wochenschr. 2013 Feb;138(8):362-6. German. https://doi.org/10.1055/s-0032-1332921
Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg. 2014 Dec;121(6):1462-73. https://doi.org/10.3171/2014.7.JNS1471
Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary. 2002;5(2):83-8. https://doi.org/10.1023/a:1022360414062
Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91. https://doi.org/10.1210/jcem.85.4.6548
Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med. 1993 Aug 1;119(3):236-40. https://doi.org/10.7326/0003-4819-119-3-199308010-00010
Wallace IR, Healy E, Cooke RS, Ellis PK, Harper R, Hunter SJ. TSH-secreting pituitary adenoma: benefits of pre-operative octreotide. Endocrinol Diabetes Metab Case Rep. 2015;2015:150007. https://doi.org/10.1530/EDM-15-0007
Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. Endocr J. 2015;62(1):21-7. https://doi.org/10.1507/endocrj.EJ14-0118
Dhillon KS, Cohan P, Kelly DF, Darwin CH, Iyer KV, Chopra IJ. Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. J Clin Endocrinol Metab. 2004 Feb;89(2):708-11. https://doi.org/10.1210/jc.2003-031629
Page KA, Roehmholdt BF, Jablonski M, Mayerson AB. Development of thyroid storm after surgical resection of a thyrotropin-secreting pituitary adenoma. Endocr Pract. 2008 Sep;14(6):732-7. https://doi.org/10.4158/EP.14.6.732
Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996 Aug;81(8):3084-90. https://doi.org/.1210/jcem.81.8.8768879
McCutcheon IE, Weintraub BD, Oldfield EH. Surgical treatment of thyrotropin-secreting pituitary adenomas. J Neurosurg. 1990 Nov;73(5):674-83. https://doi.org/10.3171/jns.1990.73.5.0674
Losa M, Mortini P, Franzin A, Barzaghi R, Mandelli C, Giovanelli M. Surgical management of thyrotropin-secreting pituitary adenomas. Pituitary. 1999 Aug;2(2):127-31. https://doi.org/10.1023/a:1009987530852
Daousi C, Foy PM, MacFarlane IA. Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):93-5. https://doi.org/10.1136/jnnp.2006.095661
Kirkman MA, Jaunmuktane Z, Brandner S, Khan AA, Powell M, Baldeweg SE. Adenomas hipofisarios activos y silenciosos que expresan hormonas estimulantes del tiroides: síntomas de presentación, tratamiento, resultados y recurrencia. World Neurosurg. 2014; 82 : 1224-1231. https://doi.org/10.4321/s1889-836x2017000200006
